Please select a Capability in order to start your service request.
FRANKLIN LAKES, N.J., February 7, 2014 – BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global technology company, today announced the appointment of Amit Bhalla as Vice President, Global Strategy and Development. Mr. Bhalla will join BD in March, 2014 and will report to Vincent A. Forlenza, Chairman, Chief Executive Officer and President.
“I am pleased to welcome Amit to our management team,” said Mr. Forlenza. “His extensive experience covering the Medical Technology industry will serve as an asset in this role. I’m confident that his proven expertise will help drive and develop BD’s strategy of accelerating growth through innovation, geographic expansion and operating effectiveness to create value for our customers and shareholders.”
Mr. Bhalla, 39, will partner with the senior management team in driving the overall development of BD’s strategy. The business development and corporate strategy functions will report to him.
He joins BD from Citi, where he served as Director – Equity Research – Life Science Tools/Medical Technology since 2006. Prior to that role, Mr. Bhalla served as Vice President – Equity Research – Emerging Medical Technology at Morgan Stanley, as well as Technical Operations/Research & Development Associate at Johnson & Johnson.
Mr. Bhalla earned his MBA from Carnegie Mellon University at the Tepper School of Business and holds a B.S. in biology from Cornell University.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.